ReShape Lifesciences Inc. (NASDAQ: RSLS) stock plunged by 0.66% at the last close whereas the RSLS stock price gains by 25% in the pre-market trading session. ReShape Lifesciences is America’s leading provider of weight-loss solutions, with a comprehensive portfolio of tried-and-true products and services for managing and treating obesity and metabolic illness.
Recent Past Development
The previously announced merger between ReShape Lifesciences and Obalon Therapeutics has been completed. Obalon renamed to ReShape Lifesciences Inc. as part of the deal, and the merged company’s common stock started trading on The NASDAQ Capital Market on June 16, 2021, under the ticker code “RSLS.”
Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences commented,
ReShape is well-positioned to benefit from the various advantages that come with being a NASDAQ-listed business, including the ability to improve shareholder value and boost awareness in the broader investing community. Completing and surpassing this major milestone is a watershed event in the existence of their organization.
After the previously reported completion of its merger with Obalon Therapeutics, ReShape Lifesciences stated that its common stock successfully traded at the first-day turnover including over 3.5 million shares on The Nasdaq Capital Market under the ticker code “RSLS.”
Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences stated,
One of RSLS’s top strategic objective has been to list on NASDAQ, and they are thrilled to have reached this essential step. They are excited to take advantage of the strengths of being a Nasdaq-listed company to further their mission of becoming the highest-rated physician-led weight loss solutions company, which is presently attached by the Lap-Band System, which has over 1,000,000 global placements, and RSLS’s recently introduced reshape care virtual health program, which is reimbursed by many major insurance carriers.